|
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a a potent agonist of the CB1 receptor and CB2 receptor with a EC50 value of 1.2 nM and 3.5 nM respectively.〔(Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982 )〕 ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a ''tert''-butyl group. An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported. ==See also== * 5F-AB-PINACA * 5F-ADB * 5F-AMB * 5F-APINACA * AB-CHFUPYCA * AB-FUBINACA * AB-PINACA * ADB-CHMINACA * ADB-PINACA * ADBICA * ADSB-FUB-187 * APINACA * MDMB-CHMICA * MDMB-FUBINACA * PF-03550096 * PX-3 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「ADB-FUBINACA」の詳細全文を読む スポンサード リンク
|